<DOC>
	<DOC>NCT01261572</DOC>
	<brief_summary>To find effective doses of ASP3550 on the maintenance of serum testosterone suppression in patients with prostate cancer.</brief_summary>
	<brief_title>Study to Find Maintenance Dose for Periodic Administration of ASP3550</brief_title>
	<detailed_description>ASP3550 is administered periodically to patients with prostate cancer. The primary efficacy variable is the effect of ASP3550 on the maintenance of serum testosterone suppression. In addition, the safety and pharmacokinetics of ASP3550 will be investigated.</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Histologically proven prostate cancer (adenocarcinoma) of all stages A patient in whom endocrine treatment is indicated. Patients with rising serum PSA after having prostatectomy or radiotherapy performed with curative intention Serum testosterone level above 2.2 ng/mL An ECOG (Eastern Cooperative Oncology Group) P.S. (Performance Status) score of 0 to 2 Serum PSA level above 2 ng/mL Previous or present endocrine treatment for prostate cancer. However, patients who have undergone neoadjuvant/adjuvant endocrine therapy for a maximal duration of 6 months and in whom prostatectomy or radiotherapy was terminated at least 6 months Treated with a 5Î±reductase inhibitor A candidate for curative therapy, i.e., radical prostatectomy or radiotherapy within 12 months Concurrent or a history of severe liver disease Abnormal ECG such as long QTc A patient receiving ASP3550 in past times Administered drug in another clinical study or a postmarket clinical study in the 28 days prior to the study</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>ASP3550</keyword>
	<keyword>Degarelix</keyword>
	<keyword>Prostate cancer</keyword>
	<keyword>Prostatic neoplasms</keyword>
</DOC>